



Final Report Date: 04-05-2016 16:06

Specimen Collected: 03-01-2016

Accession ID: 1603020057

Specimen Received: 03-02-2016 11:15

Last Name	First Name	Middle Name	Date of Birth	Gender	Physician ID
[REDACTED]	[REDACTED]		1977-07-29	Male	2096

P A T I E N T	Name: JOSH HATFIELD	P R O V I D E R	Practice Name: Monty Morris, PAC
	Date of Birth: 1977-07-29		Provider Name: Monty Morris, PAC (2096)
	Gender: Male		Street Address: 310 W. 2ND ST.
	Age: 38		City: JUSTIN
	Medical Record Number:		State: TX
	Telephone #: 469-446-8710		Zip #: 76247
	Street Address: 1699 EAST FM 550		Telephone #: 940-648-9900
	City: ROCKWALL		Fax #: 940-648-1600
	State: TX		
	Zip #: 75032		
	Email:		
	Fasting: NOT_FASTING No. of hours:		

*I WAS FASTED*

The comments in this report are meant only for clinical guidance  
Please consult your physician for medication, treatment or life style management

Nutrition	Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
	Vitamin D (ng/mL)			25	>=30		<=29	
<b>Comments</b> Likely vitamin D deficiency. Consider increasing vitamin D intake (e.g., adequate sun exposure and diet supplementation).								

**Final Report Date:** 04-05-2016 16:06

**Specimen Collected:** 03-01-2016

**Accession ID:** 1603020057

**Specimen Received:** 03-02-2016 11:15

Last Name	First Name	Middle Name	Date of Birth	Gender	Physician ID
			1977-07-29	Male	2096

Rheumatoid Arthritis	Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
	RF IgM (IU/mL)	<10			<=13		>=14	
	Anti-CCP3 IgG and IgA (U)	10			<=19	20-39	>=40	
	hs-CRP (mg/L)			5.9	<=0.9	1.0-3.0	>=3.1	

**Comments**

Calculate DAS score. If DAS 6, likely diagnosis of rheumatoid arthritis as per ACR guidelines. Consider analgesics such as NSAIDs and disease-modifying anti rheumatic drugs (DMARDs). Regular exercise recommended.

**For Physician:** Please fill in the Score column and calculate DAS Score using the following criteria.

Joint Distribution (0-5 points)	Points	Score
1 large joint	0 point	
2-10 large joints	1 point	
1-3 small joints (large joints not counted)	2 points	
4-10 small joints (large joints not counted)	3 points	
>10 joints (at least one small joint)	5 points	
<b>Acute Phase Reactants (0-1 point)</b>		
In Control hs-CRP	0 point	
Abnormal hs-CRP	1 point	
<b>Serology (0-3 points)</b>		
In Control RF and In Control CCP	0 point	
Moderate RF	2 points	
Moderate CCP	2 points	
High Risk RF	3 points	
High Risk CCP	3 points	
<b>Symptom Duration (0-1 point)</b>		
< 6 weeks	0 point	
>= 6 weeks	1 point	
<b>Total Score</b>		

If the sum of all points is greater than or equal to 6, there is likely diagnosis of Rheumatoid Arthritis



Final Report Date: 04-05-2016 16:06

Specimen Collected: 03-01-2016

Accession ID: 1603020057

Specimen Received: 03-02-2016 11:15

Last Name	First Name	Middle Name	Date of Birth	Gender	Physician ID
[REDACTED]	[REDACTED]		1977-07-29	Male	2096

ANA*	Result	Pattern	Titer
	Negative	Not Applicable	1:40

Tests flagged with \* were developed by and performance characteristics were determined by Vibrant America. Indicated tests are not FDA-cleared or approved. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. Tests flagged with \* were performed at Vibrant Genomics Tests flagged with \* were performed at Vibrant Wellness. Results of the following tests obtained with different manufacturers' assay methods may not be used interchangeably. The magnitude of the reported levels cannot be correlated to an endpoint titer. all Celiac section tests, Connective Tissue Disease section tests, and the ENA Profile-5. Laboratory Director: Mervyn Sahud, MD CLIA: 05D2078909 CLF: 06346278 Vibrant America Clinical Laboratory, 1021 Howard Avenue, Suite B, San Carlos, CA 94070. Phone: +1(866)364-0963; FAX: +1(650)508-8280; Email: support@vibrant-america.com



Final Report Date: 04-05-2016 16:06

Specimen Collected: 03-01-2016

Accession ID: 1603020057

Specimen Received: 03-02-2016 11:15

Last Name	First Name	Middle Name	Date of Birth	Gender	Physician ID
[REDACTED]	[REDACTED]		1977-07-29	Male	2096

	Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
<b>Lipids</b>	Cholesterol, Total (mg/dL)	196			<=199	200-240	>=241	
	LDL Direct (mg/dL)		129		<=99	100-129	>=130	
	HDL Direct (mg/dL)		43		>=56	35-55	<=34	
	Triglyceride (mg/dL)			273		<=149	150-200	>=201

#### Comments

Follow NCEP: ATPIII guidelines. Dietary strategies to consider include adequate intake of monounsaturated fats and omega-3 fatty acids, moderate alcohol intake, reduction of total carbohydrate to less than 50% of calories, emphasis on low glycemic-load foods and reduction of fructose, weight loss and regular exercise.